sodium zirconium (Lokelma)

following an abbreviated submission:

sodium zirconium cyclosilicate (Lokelma®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of hyperkalaemia in adult patients.

SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.

Sodium zirconium cyclosilicate offers an additional treatment choice in the therapeutic class of non-absorbed cation-exchange compounds that act as selective potassium binders.

SMC has previously issued advice for sodium zirconium cyclosilicate for the treatment of hyperkalaemia in adult patients with chronic kidney disease stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor therapy to maintain a clinically acceptable serum potassium level (normokalaemia) (SMC2288).